Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.53 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.43 |
| ▸ | ITGAL | P20701 | 2/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347089 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL1246595 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL9752652 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL6852847 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL6136566 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL7148009 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL7258586 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL150536 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL31182997 | 1.00 | ECE1 (0.53) | ECE1ITGB2ICAM1ITGALPDCD1LG2 | |
| SCHEMBL18075525 | 0.96 | ECE1 (0.56) | ECE1ITGB2ICAM1ITGALPDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668874-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | Medimmune Limited (GB) | 2020-06-24 | — | — | EP | claimed |
| WO-2019034764-A1 | PYRROLOBENZODIAZEPINE CONJUGATES | MEDIMMUNE LIMITED (GB) | 2019-02-21 | — | — | WO | claimed |
| CN-102399792-A | Cloning identification of GhNAC1 gene related to development of secondary wall of cotton fiber cell | UNIV HUAZHONG NORMAL | 2012-04-04 | — | — | CN | claimed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| CN-111989113-B | Pharmaceutical composition for treating cancer comprising guide RNA and endonuclease as active ingredients | G+FLAS生命科学有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-113710801-B | Novel immuno-PCR method using cDNA display | 爱普思隆分子进化工程株式会社 | 2024-07-09 | — | — | CN | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| WO-1994003075-A2 | MORPHOGEN-ENRICHED DIETARY COMPOSITION | CREATIVE BIOMOLECULES, INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993025246-A1 | PROSTHETIC DEVICES HAVING ENHANCED OSTEOGENIC PROPERTIES | STRYKER CORPORATION (US) | 1993-12-23 | — | — | WO | disclosed |
| EP-0573613-A1 | ENTOMOPOXVIRUS EXPRESSION SYSTEM COMPRISING SPHEROIDIN OR THYMIDINE-KINASE SEQUENCES | UNIVERSITY OF FLORIDA (US) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993013222-A1 | DNA STRUCTURE-SPECIFIC RECOGNITION PROTEIN AND USES THEREFOR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-07-08 | — | — | WO | disclosed |
| WO-1993010250-A1 | TRANSCRIPTION ADAPTORS IN EUKARYOTES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-05-27 | — | — | WO | disclosed |
| WO-1993009235-A2 | UBIQUITIN-SPECIFIC PROTEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009143-A1 | PRODUCTION AND USE OF MULTIMERIC HEMOGLOBINS | SOMATOGEN, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1992014818-A2 | ENTOMOPOXVIRUS EXPRESSION SYSTEM COMPRISING SPHEROIDIN OR THYMIDINE-KINASE SEQUENCES | UNIVERSITY OF FLORIDA (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992010518-A1 | PURIFIED SLIT PROTEIN AND SEQUENCE ELEMENTS THEREOF | YALE UNIVERSITY (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | ECE1 4185/4885ITGB2 1716/4885ICAM1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.